Neurological Biomarkers Report

WILMINGTON, DELAWARE, UNITED STATES, May 30, 2024 /EINPresswire.com/ -- Allied Market Research has recently unveiled a research study titled "Neurological Biomarkers Market Outlook and Forecast 2021-2031." This report delivers a comprehensive analysis of market risks, spotlights opportunities, and provides essential support for strategic and tactical decision-making spanning from 2021 to 2031. The study categorizes the market by pivotal regions propelling its growth and commercialization. Moreover, the report encompasses vital insights into market research and development, growth catalysts, and the evolving investment landscape within Neurological Biomarkers.

Neurological biomarkers market size was valued at $5.4 billion in 2021, and is estimated to reach $18.9 billion by 2031, growing at a CAGR of 13.6% from 2022 to 2031. Ever-increasing rise in the incidence of Alzheimer’s and Parkinson’s is anticipated to contribute toward the robust growth of neurological biomarkers among these two applications. In addition, surge in adoption of neurological biomarkers in drug development and validation has increased over the years to improve the accuracy of clinical trials. Further, rise in transition toward personalized medicine is expected to offer profitable opportunities for the expansion of neurological biomarkers applied across Alzheimer’s and Parkinson’s.

𝐊𝐄𝐘 𝐁𝐄𝐍𝐄𝐅𝐈𝐓𝐒 𝐅𝐎𝐑 𝐒𝐓𝐀𝐊𝐄𝐇𝐎𝐋𝐃𝐄𝐑𝐒

The study provides an in-depth analysis of the neurological biomarkers market forecast, future estimations and neurological biomarkers market trends to elucidate the imminent investment pockets.

It presents a quantitative analysis of the market from 2021 to 2031 to enable stakeholders to capitalize on the prevailing neurological biomarkers market opportunity.

Extensive analysis of the market based on procedures and services assists to understand the trends in the neurological biomarkers industry.

Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the neurological biomarkers industry.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞 𝐁𝐲 2031: USD 18.9 billion

Growth Rate: CAGR of 13.6%

Forecast period: 2021 - 2031

𝐁𝐲 𝐓𝐲𝐩𝐞:

Genomic

Proteomic

Metabolomic

Others

𝐁𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧:

Parkinson's Disease

Alzheimer's Disease

Multiple Sclerosis

𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧:

North America (U.S., Canada)

Europe (Germany, France, UK, Rest Of Europe)

Asia-Pacific (Japan, China, India, Rest Of Asia-Pacific)

LAMEA (Brazil, Saudi Arabia, Rest Of LAMEA)

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
Bio-Rad Laboratories, Inc.

Quanterix

merck kgaa

darmstadt

germany

bioMérieux

F. HOFFMANN-LA ROCHE LTD.

MYRIAD RBM (MYRIAD GENETICS, INC.)

PERKINELMER INC.

Thermo Fisher Scientific, Inc.

Neurobio, shimadzu corporation

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/3555

𝐓𝐡𝐞 𝐧𝐞𝐮𝐫𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐜𝐚𝐧 𝐛𝐞 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐢𝐧 𝐯𝐚𝐫𝐢𝐨𝐮𝐬 𝐰𝐚𝐲𝐬 𝐛𝐚𝐬𝐞𝐝 𝐨𝐧 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐟𝐚𝐜𝐭𝐨𝐫𝐬. 𝐇𝐞𝐫𝐞 𝐚𝐫𝐞 𝐬𝐨𝐦𝐞 𝐜𝐨𝐦𝐦𝐨𝐧 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐧𝐞𝐮𝐫𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 𝐦𝐚𝐫𝐤𝐞𝐭:

𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐓𝐲𝐩𝐞:
a. Genomic Biomarkers: This segment includes biomarkers derived from genes and their expression patterns, such as single nucleotide polymorphisms (SNPs) and gene expression profiles.
b. Proteomic Biomarkers: This segment includes biomarkers derived from proteins, such as protein expression levels, protein modifications, and protein-protein interactions.
c. Imaging Biomarkers: This segment includes biomarkers obtained through various imaging techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) scans.
d. Metabolomic Biomarkers: This segment includes biomarkers derived from metabolites, such as small molecules and metabolic pathways.
e. Others: This segment may include other types of biomarkers, such as epigenetic biomarkers or microRNA biomarkers.

𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐲𝐩𝐞:
a. Alzheimer's Disease: This segment focuses on biomarkers associated with Alzheimer's disease, such as amyloid beta and tau proteins.
b. Parkinson's Disease: This segment focuses on biomarkers associated with Parkinson's disease, such as alpha-synuclein and dopamine levels.
c. Multiple Sclerosis: This segment focuses on biomarkers associated with multiple sclerosis, such as myelin basic protein and neurofilament light chain.
d. Stroke: This segment focuses on biomarkers associated with stroke, such as brain-derived neurotrophic factor (BDNF) and glial fibrillary acidic protein (GFAP).
e. Other Neurological Disorders: This segment may include biomarkers associated with other neurological disorders, such as epilepsy, Huntington's disease, and traumatic brain injury.

𝐄𝐧𝐝 𝐔𝐬𝐞𝐫:
a. Hospitals and Clinics: This segment includes biomarker testing conducted in hospitals and clinics by healthcare professionals.
b. Research Institutes and Academic Centers: This segment focuses on biomarker research conducted in academic and research settings.
c. Diagnostic Laboratories: This segment includes biomarker testing conducted in specialized diagnostic laboratories.
d. Pharmaceutical and Biotechnology Companies: This segment focuses on biomarker discovery and development carried out by pharmaceutical and biotech companies.

𝐁𝐮𝐲 𝐍𝐨𝐰: https://www.alliedmarketresearch.com/checkout-final/9f0e3bf3e66f160fbacb254909054633

𝐎𝐮𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐏𝐫𝐨𝐯𝐢𝐝𝐞𝐬 𝐘𝐨𝐮 𝐀𝐧𝐬𝐰𝐞𝐫 𝐭𝐨 𝐁𝐞𝐥𝐨𝐰 𝐌𝐞𝐧𝐭𝐢𝐨𝐧𝐞𝐝 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧:

• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2023?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?

𝐀𝐕𝐄𝐍𝐔𝐄- 𝐀 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐁𝐚𝐬𝐞𝐝 𝐋𝐢𝐛𝐫𝐚𝐫𝐲 (𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐨𝐧-𝐝𝐞𝐦𝐚𝐧𝐝, 𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐛𝐚𝐬𝐞𝐝 𝐩𝐫𝐢𝐜𝐢𝐧𝐠 𝐦𝐨𝐝𝐞𝐥) 𝐎𝐟𝐟𝐞𝐫𝐞𝐝 𝐛𝐲 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (220+ 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬) @ https://www.alliedmarketresearch.com/purchase-enquiry/3555

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐌𝐨𝐫𝐞 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Neurological Biomarkers Market: https://www.alliedmarketresearch.com/neurological-biomarkers-market
Next Generation Diabetes Therapy and Drug Delivery Market: https://www.alliedmarketresearch.com/next-generation-diabetes-therapy-and-drug-delivery-market
Automated Liquid Handling Market: https://www.alliedmarketresearch.com/automated-liquid-handling-market

𝐀𝐛𝐨𝐮𝐭 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:

David Correa

Portland, OR, United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

David Correa
Allied Market Research
+ 18007925285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Other

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.